NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TARS

Tarsus Pharmaceuticals Inc

May 22 • 04:00PM ET

42.97

Dollar change -0.22
Percentage change -0.51	%

Healthcare • Biotechnology • USA • NASD

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: VTI IWM VXF IWO VTWO IBB PJP SCHA XPH VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	15.01%	Shs Outstand	42.00M	Perf Week	-1.22%
Market Cap	1.81B	Forward P/E	23.57	EPS next Y	1.82	Insider Trans	-1.07%	Shs Float	35.71M	Perf Month	-14.06%
Income	-104.94M	PEG	-	EPS next Q	-0.39	Inst Own	101.08%	Short Float	23.27%	Perf Quarter	-10.18%
Sales	233.67M	P/S	7.73	EPS this Y	61.77%	Inst Trans	-11.02%	Short Ratio	11.29	Perf Half Y	-3.72%
Book/sh	8.15	P/B	5.27	EPS next Y	255.34%	ROA	-24.69%	Short Interest	8.31M	Perf Year	10.95%
Cash/sh	9.71	P/C	4.43	EPS next 5Y	-	ROE	-33.98%	52W Range	20.08 - 57.28	Perf YTD	-22.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-66.60%	ROI	-25.32%	52W High	-24.98%	Beta	0.86
Dividend TTM	-	Quick Ratio	5.54	Sales past 5Y	172.29%	Gross Margin	92.99%	52W Low	113.97%	ATR (14)	2.24
Dividend Ex-Date	-	Current Ratio	5.57	EPS Y/Y TTM	42.86%	Oper. Margin	-46.72%	RSI (14)	38.96	Volatility	2.77% 2.97%
Employees	323	Debt/Eq	0.21	Sales Y/Y TTM	449.03%	Profit Margin	-44.91%	Recom	1.25	Target Price	70.86
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	36.93%	Payout	-	Rel Volume	0.48	Prev Close	43.19
Sales Surprise	8.15%	EPS Surprise	12.32%	Sales Q/Q	183.68%	Earnings	May 01 AMC	Avg Volume	736.15K	Price	42.97
SMA20	-7.16%	SMA50	-10.17%	SMA200	-1.74%	Trades		Volume	350,700	Change	-0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Loading…
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
04:05PM	Loading…
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
08:30AM	Loading…
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86% +12.20%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99% -5.53%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azamian Bobak R.	President/CEO and Board Chair	Mar 24 '25	Sale	50.00	6,000	300,000	824,106	Mar 26 04:47 PM
Azamian Bobak R.	Officer	Mar 24 '25	Proposed Sale	50.00	6,000	300,000		Mar 24 05:35 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '25	Sale	46.29	3,643	168,634	71,979	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20 '25	Sale	50.11	3,365	168,620	65,057	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '25	Sale	47.40	3,557	168,602	68,422	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '25	Sale	50.11	2,435	122,018	79,682	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '25	Sale	46.29	2,605	120,585	84,660	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '25	Sale	47.40	2,543	120,538	82,117	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 18 '25	Sale	46.29	3,341	154,655	58,057	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 19 '25	Sale	47.40	3,261	154,571	54,796	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 20 '25	Sale	50.11	3,084	154,539	51,712	Mar 20 09:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '25	Sale	46.29	2,315	107,161	50,751	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20 '25	Sale	50.11	2,137	107,085	46,355	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '25	Sale	47.40	2,259	107,077	48,492	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20 '25	Sale	50.11	8,534	427,639	53,635	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '25	Sale	47.40	8,551	405,317	62,169	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '25	Sale	46.29	7,131	330,094	70,720	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 19 '25	Sale	47.40	1,254	59,440	23,617	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 18 '25	Sale	46.29	1,284	59,436	24,871	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 20 '25	Sale	50.11	1,186	59,430	22,431	Mar 20 09:48 PM
Whitfield Dianne C.	Officer	Mar 20 '25	Proposed Sale	50.11	2,137	107,093		Mar 20 04:35 PM
Farrow Jeffrey S	Officer	Mar 20 '25	Proposed Sale	50.11	1,186	59,435		Mar 20 04:30 PM
Mottiwala Aziz	Officer	Mar 20 '25	Proposed Sale	50.11	3,365	168,632		Mar 20 04:29 PM
Wahl Bryan	Officer	Mar 20 '25	Proposed Sale	50.11	3,084	154,550		Mar 20 04:21 PM
Neervannan Seshadri	Officer	Mar 20 '25	Proposed Sale	50.11	2,435	122,026		Mar 20 04:18 PM
Azamian Bobak R.	Officer	Mar 20 '25	Proposed Sale	50.11	8,534	427,669		Mar 20 04:11 PM
Neervannan Seshadri	Officer	Mar 19 '25	Proposed Sale	47.40	2,543	120,536		Mar 19 03:27 PM
Wahl Bryan	Officer	Mar 19 '25	Proposed Sale	47.40	3,261	154,569		Mar 19 03:24 PM
Azamian Bobak R.	Officer	Mar 19 '25	Proposed Sale	47.40	8,551	405,311		Mar 19 03:23 PM
Whitfield Dianne C.	Officer	Mar 19 '25	Proposed Sale	47.40	2,259	107,075		Mar 19 03:22 PM
Farrow Jeffrey S	Officer	Mar 19 '25	Proposed Sale	47.40	1,254	59,439		Mar 19 03:12 PM
Mottiwala Aziz	Officer	Mar 19 '25	Proposed Sale	47.40	3,557	168,599		Mar 19 03:12 PM
Neervannan Seshadri	Officer	Mar 18 '25	Proposed Sale	46.28	2,605	120,571		Mar 18 04:31 PM
Wahl Bryan	Officer	Mar 18 '25	Proposed Sale	46.28	3,341	154,637		Mar 18 04:26 PM
Mottiwala Aziz	Officer	Mar 18 '25	Proposed Sale	46.28	3,643	168,614		Mar 18 04:26 PM
Whitfield Dianne C.	Officer	Mar 18 '25	Proposed Sale	46.28	2,315	107,149		Mar 18 04:20 PM
Azamian Bobak R.	Officer	Mar 18 '25	Proposed Sale	46.28	7,131	330,055		Mar 18 04:15 PM
Farrow Jeffrey S	Officer	Mar 18 '25	Proposed Sale	46.28	1,284	59,429		Mar 18 04:12 PM
Goldberg Andrew D.	Director	Mar 07 '25	Option Exercise	12.89	7,000	90,230	13,350	Mar 11 04:01 PM
LINK WILLIAM J PHD	Director	Aug 12 '24	Sale	26.08	35,000	912,961	0	Aug 14 04:34 PM
FLYING L PARTNERS XI LLC	Director	Aug 12 '24	Proposed Sale	26.85	35,000	939,750		Aug 12 04:25 PM
Farrow Jeffrey S	See Remarks	Jun 18 '24	Sale	27.47	10,445	286,924	18,136	Jun 20 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARS

Tarsus Pharmaceuticals Inc

Upgrade your FINVIZ experience